Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain

Human Gene Therapy

Volumn 23, Issue 8, 2012, Pages 891-902

  Salegio, Ernesto A ^a   Samaranch, Lluis ^a   Jenkins, Russell W ^b   Clarke, Christopher J ^b,c   Lamarre, Clementine ^a   Beyer, Janine ^a   Kells, Adrian P ^a   Bringas, John ^a   Sebastian, Waldy San ^a   Richardson, R Mark ^a   Rosenbluth, Kate H ^a   Hannun, Yusuf A ^b,c   Bankiewicz, Krystof S ^a   Forsayeth, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANTES; SPHINGOMYELIN PHOSPHODIESTERASE;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; ENZYME ACTIVITY; INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; RAT; SEROTYPE; UPREGULATION;

ANIMALS; BRAIN; CHEMOKINE CCL5; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NIEMANN-PICK DISEASES; RATS; RATS, SPRAGUE-DAWLEY; SPHINGOMYELIN PHOSPHODIESTERASE; UP-REGULATION;

EID: 84865208842     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.052     Document Type: Article

References (36)

1. Amalfitano, A., McVie-Wylie, A.J., Hu, H., et al. (1999). Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-a-glucosidase. Proc. Natl. Acad. Sci. U.S.A. 96, 8861-8866.
2. Ayuso, E., Mingozzi, F., Montane, J., et al. (2010). High AAV vector purity results in serotype-and tissue-independent enhancement of transduction efficiency. Gene Ther. 17, 503-510.
3. Barranger, J.M., and Novelli, E.A. (2001). Gene therapy for lyso-somal storage disorders. Expert Opin. Biol. Ther. 1, 857-867.
4. Bielawski, J., Szulc, Z.M., Hannun, Y.A., et al. (2006). Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39, 82-91.
5. Bosch, A., Perret, E., Desmaris, N., et al. (2000). Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther. 11, 1139-1150.
6. Cearley, C.N., and Wolfe, J.H. (2007). A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci. 27, 9928-9940.
7. Dhami, R., and Schuchman, E.H. (2004). Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: Implications for Niemann-Pick disease enzyme replacement therapy. J. Biol. Chem. 279, 1526-1532.
8. Dodge, J.C., Clarke, J., Song, A., et al. (2005). Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc. Natl. Acad. Sci. U.S.A. 102, 17822-17827.
9. Foust, K.D., Nurre, E., Montgomery, C.L., et al. (2009). In-travascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59-65.
10. Graber, D., Salvayre, R., and Levade, T. (1994). Accurate differentiation of neuronopathic and nonneuronopathic forms of Niemann-Pick disease by evaluation of the effective residual lysosomal sphingomyelinase activity in intact cells. J. Neu-rochem. 63, 1060-1068.
11. Gray, S.J., Matagne, V., Bachaboina, L., et al. (2011). Preclinical differences of intravascular AAV9 delivery to neurons and glia: A comparative study of adult mice and nonhuman primates. Mol. Ther. 19, 1058-1069.
12. He, X., Miranda, S.R., Xiong, X., et al. (1999). Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells. Biochim. Bio-phys. Acta 1432, 251-264.
13. Hsich, G., Sena-Esteves, M., and Breakefield, X.O. (2002). Critical issues in gene therapy for neurologic disease. Hum. Gene Ther. 13, 579-604.
14. Jenkins, R.W., Canals, D., and Hannun, Y.A. (2009). Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal. 21, 836-846.
15. Jenkins, R.W., Canals, D., Idkowiak-Baldys, J., et al. (2010). Regulated secretion of acid sphingomyelinase: Implications for selectivity of ceramide formation. J. Biol. Chem. 285, 35706-35718.
16. Jenkins, R.W., Clarke, C.J., Canals, D., et al. (2011). Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase. J. Biol. Chem. 286, 13292-13303.
17. Kells, A.P., Hadaczek, P., Yin, D., et al. (2009). Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc. Natl. Acad. Sci. U.S.A. 106, 2407-2411.
18. Kim, E.Y., Hong, Y.B., Lai, Z., et al. (2004). Expression and secretion of human glucocerebrosidase mediated by recombinant lentivirus vectors in vitro and in vivo: Implications for gene therapy of Gaucher disease. Biochem. Biophys. Res. Commun. 318, 381-390.
19. Kitagawa T. (1987). An animal model of human acid sphingo-myelinase deficiency (Niemann-Pick disease) and the study of its enzyme replacement (the Japan Society of Human Genetics award lecture). Jinrui Idengaku Zasshi 32, 55-69.
20. Levy, J.A. (2009). The unexpected pleiotropic activities of RANTES. J. Immunol. 182, 3945-3946.
21. Matsushita, T., Elliger, S., Elliger, C., et al. (1998). Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5, 938-945.
22. Miranda, S.R., He, X., Simonaro, C.M., et al. (2000). Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. 14, 1988-1995.
23. Otterbach, B., and Stoffel, W. (1995). Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell 81, 1053-1061.
24. Passini, M.A., Macauley, S.L., Huff, M.R., et al. (2005). AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol. Ther. 11, 754-762.
25. Passini, M.A., Bu, J., Fidler, J.A., et al. (2007). Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc. Natl. Acad. Sci. U.S.A. 104, 9505-9510.
26. Peltola, M., Kyttala, A., Heinonen, O., et al. (1998). Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse. Gene Ther. 5, 1314-1321.
27. Salegio, E.A., Kells, A.P., Richardson, R.M., et al. (2010). Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lyso-somal storage disorders. Hum. Gene Ther. 21, 1093-1103.
28. Schissel, S.L., Keesler, G.A., Schuchman, E.H., et al. (1998). The cellular trafficking and zinc dependence of secretory and ly-sosomal sphingomyelinase, two products of the acid sphin-gomyelinase gene. J. Biol. Chem. 273, 18250-18259.
29. Skuljec, J., Sun, H., Pul, R., et al. (2011). CCL5 induces a pro-inflammatory profile in microglia in vitro. Cell Immunol. 270, 164-171.
30. Theilmeier, G., Schmidt, C., Herrmann, J., et al. (2006). High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 114, 1403-1409.
31. Watson, D.J., and Wolfe, J.H. (2003). Lentiviral vectors for gene transfer to the central nervous system: Applications in lyso-somal storage disease animal models. Methods Mol. Med. 76, 383-403.
32. Yin, D., Forsayeth, J., and Bankiewicz, K.S. (2010). Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J. Neurosci. Methods 187, 46-51.
33. Zeidan, Y.H., and Hannun, Y.A. (2010). The acid sphingomye-linase/ ceramide pathway: Biomedical significance and mechanisms of regulation. Curr. Mol. Med. 10, 454-466.
34. Zhang, X.S., Brondyk, W., Lydon, J.T., et al. (2011). Biother-apeutic target or sink: Analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases. J. Inherit. Metab. Dis 34, 795-809.
35. Zhou, H., Linke, R.P., Schaefer, H.E., et al. (1995). Progressive liver failure in a patient with adult Niemann-Pick disease associated with generalized AL amyloidosis. Virchows Arch. 426, 635-639.
36. Ziegler, R.J., Yew, N.S., Li, C., et al. (1999). Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum. Gene Ther. 10, 1667-1682.